Phase 3 randomized EORTC 1325-MG/KEYNOTE-054 study results: pembrolizumab versus placebo after complete resection in patients with high-risk stage III melanoma.
dc.contributor.author | Khattak, A | |
dc.contributor.author | Robert, C | |
dc.contributor.author | Blank, C | |
dc.contributor.author | Mandala, M | |
dc.contributor.author | Long, G | |
dc.contributor.author | Atkinson, V | |
dc.contributor.author | Dalle, S | |
dc.contributor.author | Haydon, A | |
dc.contributor.author | Lichinitser, M | |
dc.contributor.author | Carlino, M | |
dc.contributor.author | Sandhu, S | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Puig, S | |
dc.contributor.author | Ascierto, P | |
dc.contributor.author | Rutkowski, P | |
dc.contributor.author | Schadendorf, D | |
dc.contributor.author | Lorigan, Paul C | |
dc.contributor.author | Ibrahim, N | |
dc.contributor.author | Suciu, S | |
dc.contributor.author | Eggermont, A | |
dc.date.accessioned | 2018-09-10T21:07:51Z | |
dc.date.available | 2018-09-10T21:07:51Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Phase 3 randomized EORTC 1325-MG/KEYNOTE-054 study results: pembrolizumab versus placebo after complete resection in patients with high-risk stage III melanoma. 2018, 14: 48-48 Asia Pac J Clin Oncol | en |
dc.identifier.uri | http://hdl.handle.net/10541/621219 | |
dc.language.iso | en | en |
dc.title | Phase 3 randomized EORTC 1325-MG/KEYNOTE-054 study results: pembrolizumab versus placebo after complete resection in patients with high-risk stage III melanoma. | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Fiona Stanley Hospital/University of Western Australia, Perth, Australia | en |
dc.identifier.journal | Asia-Pacific Journal of Clinical Oncology | en |